• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

FDA rejects Xspray's would-be rival to Bristol Myers' Sprycel on dosing,...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jul 12, 2023 at 09:52: AM
via With Xspray Pharma and Eversana’s cancer med hitting a regulatory setback, a launch in the second half of 2023 now looks unlikely. That’s good news for Bristol Myers Squibb, which has secured a few more competition-free months for its aging leukemia blockbuster Sprycel.

article source
 

<



Similar threads

cafead
FDA Rejects Rocket’s Gene Therapy, Cites Need for Additional CMC Info
Replies
0
Views
49
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA Rejects Aldeyra’s Dry Eye Drug, Cites Need for Additional Trial
Replies
0
Views
220
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA Rejects Alvotech’s Stelara Biosimilar as Manufacturing Problems Continue
Replies
0
Views
175
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA Rejects Lilly’s Eczema Treatment Over Third-Party Manufacturing Issues
Replies
0
Views
113
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA Adcomm Rejects BrainStorm’s ALS Therapy in Nearly Unanimous Vote
Replies
0
Views
135
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote